Aurinia Pharmaceuticals (AUPH) announced that the Japanese Ministry of Health, Labour, and Welfare has approved LUPKYNIS or voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil to treat lupus nephritis.
The company's collaboration partner, Otsuka Pharmaceutical, filed the new drug application with Japanese regulatory authorities in November 2023. Aurinia and Otsuka entered a collaboration and licensing agreement in 2020 for the development and commercialization of oral voclosporin in the EU, Japan, the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein, and Ukraine. Aurinia is eligible to receive a payment of $10 million upon approval in Japan along with low double-digit royalties on net sales once launched.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.